New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
14:33 EDTISISIsis Pharmaceuticals provides update on CHMP Opinion on KYNAMRO
Isis Pharmaceuticals announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application for KYNAMROTM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia. The FDA approved KYNAMRO in the United States in January for the treatment of patients with Homozygous Familial Hypercholesterolaemia.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ISIS

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use